Kong, MD, PhD, MBA
Garheng is founder and managing partner of HealthQuest Capital and has served as a member of our board of directors since September 2015. He brings over 20 years of clinical, technical, and business experience in creating and building high-growth and innovation-based healthcare businesses. He currently serves on the board of directors of Alimera Sciences, Castle Biosciences, Cempra, Duke University Medical Center, First Aid Shot Therapy, Histogenics, Laboratory Corporation of America, Trice Medical, and VirMedica. He previously served on the board of directors of Applied Genetic Technology Corp., Proteon, TransEnterix, Calibra Medical (acquired by J&J), Cellective (acquired by AstraZeneca), Serenex (acquired by Pfizer), NovaMin (acquired by GSK), Salveo Specialty Pharmacy (acquired by Catamaran), SARCode (acquired by Shire), and numerous industry groups. Garheng’s early career included positions at GlaxoSmithKline, McKinsey, and TherOx before he started his investing career.
Garheng earned his MD, PhD, and MBA from Duke University and received 2 undergraduate degrees in chemical engineering and biological sciences from Stanford University.